Ph 3 trial of Anbenitamab (KN026) + Docetaxel For Injection (Albumin-Bound) (HB1801) For 1L HER2+ve Advanced Breast Cancer Meets Primary Endpoint
Phase III clinical study (Study Protocol No.: KN026-003) of Anbenitamab (‘‘KN026’’), co-developed by Shanghai JMT-BIO Technology Co., Ltd. (‘‘JMT-BIO’’), a subsidiary of the Company, and Jiangsu Alphamab Oncology Co., Ltd., in combination with the Group’s self-developed Docetaxel for Injection (Albumin-bound) (‘‘HB1801’’) for the first-line treatment of HER2-positive advanced breast cancer has successfully met the pre-specified primary endpoint of progression-free survival (‘‘PFS’’) as assessed by the Independent Data Monitoring Committee (the ‘‘IDMC’’), yielding results that are both statistically significant and clinically meaningful, with a favourable safety profile.
Share:
More News
Reagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: “The dosing of patients marks an important milestone for Anocca, and demonstrates our ability to develop, manufacture and clinically deploy precision TCR-T cell therapy products. The novel ANOC-001 clinical candidate was developed with Anocca’s proprietary analytical platform that maps targets
“The clinical experience in 81 patients validates both EBTATE and the broader Evans Blue platform,” said Chris Pak, Chairman and Chief Executive Officer of MTTI. “By improving tumor delivery and retention while requiring only approximately 12.5% of the cumulative radioactivity administered in current standard-of-care PRRT, the platform has the potential
Leslie Chong, Managing Director and CEO of Imugene, commented: “FDA Fast Track Designation for both CLL/SLL and MZL reflects the meaningful clinical activity we are seeing with azer-cel across multiple B-cell malignancies. For patients who have exhausted standard treatment options in these indications, we believe azer-cel represents a genuinely promising
“Our approach to innovation in cancer care is grounded in real-world impact, both advancing treatment and improving how care is delivered,” said Olivier Nataf, Global Head of Oncology at Sanofi. “Sarclisa, which has been prescribed to nearly 70,000 patients worldwide, already brings a well-established safety and efficacy profile across the